Last mentioned: Mar 22, 2026
Across the most recent 1 story covering Olema Pharmaceuticals — 100% neutral sentiment, averaging 5/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Commercial Launch
Target date for the market entry of palazestrant for ER+ breast cancer treatment.
Institutional Stake Disclosure
Reports surfaced regarding a significant $122 million position held by a major investor.
Price Target Hike
Wall Street analysts raised the price target for OLMA to $62.00, citing clinical optimism.
Earnings & SEC Filing
Olema reported quarterly results and filed an 8-K detailing its financial condition.
Olema Pharmaceuticals (OLMA) has delivered a massive 242% return over the past year, fueled by clinical progress in its lead breast cancer candidate, palazestrant. A recent $122 million institutional position has sparked debate over whether the biotech firm still has significant room for growth ahead of a projected 2027 launch.
Source: finance.yahoo.com · fool.com
This page surfaces every story mentioning Olema Pharmaceuticals across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Olema Pharmaceuticals was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |